Cytokinetics Inc is committed to improving the lives of patients by developing innovative therapies in the field of muscle biology. The company's core values include integrity, collaboration, and dedication to scientific excellence. Cytokinetics is driven by a corporate philosophy that emphasizes scientific rigor, patient-centricity, and a strong commitment to advancing medical knowledge. By working closely with key stakeholders, including healthcare professionals and patients, Cytokinetics aims to address unmet medical needs and make a positive impact on global healthcare. With its cutting-edge research and development efforts, Cytokinetics Inc strives to bring new treatment options to patients suffering from serious diseases and disorders affecting muscle function.

Cytokinetics Inc is primarily present in the United States.

Cytokinetics Inc has achieved significant milestones in its journey. One notable achievement is the development of omecamtiv mecarbil, a potential treatment for heart failure. The company has successfully completed various clinical trials, demonstrating promising results in improving cardiac function. Additionally, Cytokinetics Inc has advanced its research in muscle biology and therapeutics, leading to collaborations with renowned pharmaceutical companies and medical institutions. Furthermore, the company's continuous dedication to innovation and scientific excellence has resulted in numerous patents and publications. These milestones highlight Cytokinetics Inc's commitment to delivering innovative solutions and advancing the field of cardiac and skeletal muscle disorders.

Cytokinetics Inc is a renowned biopharmaceutical company specializing in the discovery and development of muscle biology-focused therapies. Established in 1997, the company has emerged as a leading player in the field, harnessing the power of sarcomere-directed drug candidates. Cytokinetics' innovative research and development aim to address diseases associated with muscle impairment and dysfunction. With a strong focus on cardiovascular and neuromuscular diseases, Cytokinetics Inc continues to progress its pipeline of potential treatments with the goal of improving patients' lives. Their commitment to scientific advancement and clinical collaboration places Cytokinetics Inc at the forefront of efforts to tackle serious medical conditions.

The main competitors of Cytokinetics Inc in the market include pharmaceutical companies such as Amgen, Biogen, and Novartis. These companies also specialize in the development of cutting-edge therapies and drugs for various medical conditions. However, Cytokinetics Inc distinguishes itself through its novel approach to drug discovery, focusing on the field of muscle biology and developing potential treatments for diseases related to muscle dysfunction. With its innovative research and development strategies, Cytokinetics Inc aims to make significant contributions to the pharmaceutical industry and provide solutions that address unmet medical needs.

Cytokinetics Inc is primarily active in the pharmaceutical and biotechnology industries.

The business model of Cytokinetics Inc is focused on the discovery and development of novel muscle activators as potential treatments for debilitating diseases. Cytokinetics utilizes its expertise in muscle biology to develop small molecule drug candidates that target muscle function and address diseases such as amyotrophic lateral sclerosis (ALS), spinal muscular atrophy (SMA), and hypertrophic cardiomyopathy (HCM). By designing innovative therapies that aim to improve muscle performance, Cytokinetics aims to provide hope for patients suffering from these conditions and enhance their overall quality of life through its scientific research and drug development efforts.

Cytokinetics의 P/E 비율은 -7.66입니다.

Cytokinetics의 P/S 비율은 739.84입니다.

Cytokinetics에 대한 AlleAktien 품질 점수는 4/10입니다.

예상되는 Cytokinetics 매출은 6.55 백만 USD입니다.

예상되는 Cytokinetics 이익은 -633.24 백만 USD입니다.

Cytokinetics Inc. is a biopharmaceutical company based in South San Francisco, California. The company specializes in the development of novel therapeutics for severe, chronic diseases of the heart muscle and skeletal muscle. It utilizes expertise in cell biology, medical technology, and drug development to create precision medicine therapies tailored to clinical needs. The company has two main divisions: Cardiovascular and Neuromuscular. The Cardiovascular division focuses on developing therapeutics for diseases of the heart muscle and blood vessels. This includes heart muscle diseases such as heart failure and arrhythmias, as well as vascular diseases such as peripheral arterial disease and pulmonary arterial hypertension. The Neuromuscular division specializes in developing therapeutics for diseases of the skeletal muscle. This includes neuromuscular diseases such as spinal muscular atrophy, amyotrophic lateral sclerosis, and Duchenne muscular dystrophy. Cytokinetics develops its therapeutics using an innovative class of drugs known as myosin activators. A myosin activator is a substance that activates the enzyme myosin, which is responsible for muscle contraction. By activating myosin, the muscle can work better and more effectively. One of Cytokinetics' key products is the investigational drug Omecamtiv Mercabil. It is an oral myosin activator for the treatment of heart failure. Omecamtiv's mechanism is aimed at increasing the contractile force of the heart muscle to improve blood flow and pumping. The continuous research and development of drugs like Omecamtiv Mercabil have the potential to usher in a new era of treatment for cardiovascular diseases. Cytokinetics also has a partnership with Astellas Pharma Inc. for the joint development of Reldesemtiv for spinal muscular atrophy, CK-274 for hypertrophic cardiomyopathy, and other neuromuscular indications. Collaborating with partners increases the likelihood of rapid and successful drug development and accelerates market introduction. Cytokinetics' business model is based on partnerships with other companies to accelerate the research and development of therapeutics for severe, chronic diseases of the heart muscle and skeletal muscle. By leveraging innovative technologies and platforms, and integrating data, human experience, and scientific intelligence, Cytokinetics brings novel medicines to market that could improve the quality of life for millions of patients worldwide.

Cytokinetics은(는) 연간 번의 배당을 통해 0 USD의 배당금을 지급합니다.

Cytokinetics의 현재 배당금은 계산할 수 없거나, 회사가 배당금을 지급하지 않습니다.

Cytokinetics의 ISIN은 US23282W6057입니다.

Cytokinetics의 WKN은 A1W1KK입니다.

Cytokinetics의 티커는 CYTK입니다.

지난 12개월 동안 Cytokinetics은(는) 의 배당금을 지급했습니다. 이는 약 의 배당 수익률에 해당합니다. 향후 12개월 동안 Cytokinetics은(는) 0 USD의 배당금을 지급할 것으로 예상됩니다.

Cytokinetics의 현재 배당 수익률은 입니다.

Cytokinetics은 분기별로 배당금을 지급합니다. 이는 월에 배당됩니다.

Cytokinetics은(는) 지난 0년 동안 매년 배당금을 지급했습니다.

향후 12개월 동안 0 USD의 배당금이 예상됩니다. 이는 배당수익률 0 %에 해당합니다.

Cytokinetics은 '건강' 섹터에 속합니다.

Cytokinetics의 마지막 배당금을 0 USD만큼 받기 위해선 의 Ex-Tag 전에 주식을 보유하고 있어야 했습니다.

마지막 배당금 지급일은 입니다.

2023년에 Cytokinetics는 0 USD를 배당금으로 지급했습니다.

Cytokinetics의 배당금은 USD에 지급됩니다.